Published in J Cereb Blood Flow Metab on March 03, 2010
Acute Stroke Imaging Research Roadmap II. Stroke (2013) 1.47
Blood-brain barrier disruption after cardiac surgery. AJNR Am J Neuroradiol (2012) 0.93
Method parameters' impact on mortality and variability in rat stroke experiments: a meta-analysis. BMC Neurosci (2013) 0.88
Detrimental role of the EP1 prostanoid receptor in blood-brain barrier damage following experimental ischemic stroke. Sci Rep (2015) 0.84
Temporal analysis of blood-brain barrier disruption and cerebrospinal fluid matrix metalloproteinases in rhesus monkeys subjected to transient ischemic stroke. J Cereb Blood Flow Metab (2016) 0.78
Inflammation in neuroviral diseases. J Neural Transm (Vienna) (2010) 0.78
Electroacupuncture ameliorates post-stroke learning and memory through minimizing ultrastructural brain damage and inhibiting the expression of MMP-2 and MMP-9 in cerebral ischemia-reperfusion injured rats. Mol Med Rep (2016) 0.76
The Role of Matrix Metalloproteinase Polymorphisms in Ischemic Stroke. Int J Mol Sci (2016) 0.75
Importance of Contrast-Enhanced Fluid-Attenuated Inversion Recovery Magnetic Resonance Imaging in Various Intracranial Pathologic Conditions. Korean J Radiol (2016) 0.75
Hydrogen improves neurological function through attenuation of blood-brain barrier disruption in spontaneously hypertensive stroke-prone rats. BMC Neurosci (2015) 0.75
Circulating matrix metalloproteinases in children with diabetic ketoacidosis. Pediatr Diabetes (2016) 0.75
ApoE Influences the Blood-Brain Barrier Through the NF-κB/MMP-9 Pathway After Traumatic Brain Injury. Sci Rep (2017) 0.75
Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke (1989) 21.77
Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke (1995) 6.49
Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med (2006) 5.10
Matrix metalloproteinases in neuroinflammation. Glia (2002) 3.51
Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol (2007) 3.33
Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke (1998) 3.03
Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol (2005) 2.59
Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol (2004) 2.54
Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab (1999) 2.41
Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke (2002) 2.30
Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke (2004) 2.26
Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke (2008) 2.10
Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab (1996) 1.99
Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J Neurosci (2006) 1.85
Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol (2008) 1.79
Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke (2001) 1.73
Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke (1995) 1.71
Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke (2001) 1.69
Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab (1998) 1.63
Responses of endothelial cell and astrocyte matrix-integrin receptors to ischemia mimic those observed in the neurovascular unit. Stroke (2007) 1.58
Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke (2007) 1.47
Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab (1996) 1.37
Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J Cereb Blood Flow Metab (2007) 1.30
Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Stroke (2009) 1.26
Visualization of intravenously administered contrast material in the CSF on fluid-attenuated inversion-recovery MR images: an in vitro and animal-model investigation. AJNR Am J Neuroradiol (2000) 1.23
Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res (2007) 1.19
Zymographic measurement of gelatinase activity in brain tissue after detergent extraction and affinity-support purification. J Neurosci Methods (1997) 1.19
Verification of enhancement of the CSF space, not parenchyma, in acute stroke patients with early blood-brain barrier disruption. J Cereb Blood Flow Metab (2007) 1.13
Genetic hypertension and increased susceptibility to cerebral ischemia. Neurosci Biobehav Rev (1992) 1.13
DNA scission after focal brain ischemia. Temporal differences in two species. Stroke (1997) 1.11
A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke (2005) 1.08
Monocyte chemoattractant protein-1 in the choroid plexus: a potential link between vascular pro-inflammatory mediators and the CNS during peripheral tissue inflammation. Neuroscience (2008) 1.05
Dynamics of cerebral injury, perfusion, and blood-brain barrier changes after temporary and permanent middle cerebral artery occlusion in the rat. J Neurol Sci (1999) 1.05
The effects of cerebral ischemia on the rat choroid plexus. J Cereb Blood Flow Metab (2006) 0.99
Choroid plexus recovery after transient forebrain ischemia: role of growth factors and other repair mechanisms. Cell Mol Neurobiol (2000) 0.99
Bone marrow-derived cells are the major source of MMP-9 contributing to blood-brain barrier dysfunction and infarct formation after ischemic stroke in mice. Brain Res (2009) 0.98
Reperfusion-associated hemorrhagic transformation in SHR rats: evidence of symptomatic parenchymal hematoma. Stroke (2008) 0.93
Blood-brain barrier disruption in experimental focal ischemia: comparison between in vivo MRI and immunocytochemistry. Magn Reson Imaging (1994) 0.93
Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade. J Hypertens (2005) 0.92
Hypoxia-ischemia, but not hypoxia alone, induces the expression of heme oxygenase-1 (HSP32) in newborn rat brain. J Cereb Blood Flow Metab (1997) 0.84
Disruption of the blood-cerebrospinal fluid barrier by transient cerebral ischemia. Brain Res (1994) 0.83
Identification of pro-angiogenic markers in blood vessels from stroked-affected brain tissue using laser-capture microdissection. BMC Genomics (2009) 0.83
Choroid plexus electrolytes and ultrastructure following transient forebrain ischemia. Am J Physiol (1995) 0.82
Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet (2007) 8.68
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke (2003) 7.75
Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol (2009) 6.02
MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol (2012) 5.91
Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA (2004) 4.82
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke (2004) 4.39
Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol (2008) 3.98
Ischemic tolerance and endogenous neuroprotection. Trends Neurosci (2003) 3.44
DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol (2011) 3.18
Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke (2006) 3.03
Recommendations for imaging of acute ischemic stroke: a scientific statement from the American Heart Association. Stroke (2009) 2.55
Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol (2004) 2.54
Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke (2013) 2.50
Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol (2004) 2.30
Diagnostic and prognostic value of early MR Imaging vessel signs in hyperacute stroke patients imaged <3 hours and treated with recombinant tissue plasminogen activator. AJNR Am J Neuroradiol (2005) 2.28
Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke (2004) 2.26
A 62-year-old man with fluctuating neurological deficits and skin lesions. JAMA Neurol (2013) 1.99
An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol (2003) 1.97
Establishing final infarct volume: stroke lesion evolution past 30 days is insignificant. Stroke (2008) 1.94
Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J Cereb Blood Flow Metab (2003) 1.93
Intra- and interrater reliability of ischemic lesion volume measurements on diffusion-weighted, mean transit time and fluid-attenuated inversion recovery MRI. Stroke (2006) 1.77
Association of ischemic lesion patterns on early diffusion-weighted imaging with TOAST stroke subtypes. Arch Neurol (2003) 1.77
Protein SUMOylation is massively increased in hibernation torpor and is critical for the cytoprotection provided by ischemic preconditioning and hypothermia in SHSY5Y cells. J Cereb Blood Flow Metab (2006) 1.75
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum (2008) 1.73
Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke (2002) 1.71
Acute stroke imaging research roadmap. Stroke (2008) 1.66
Validation of an acute ischemic stroke model: does diffusion-weighted imaging lesion volume offer a clinically significant improvement in prediction of outcome? Stroke (2007) 1.65
Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience. Stroke (2003) 1.62
Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res (2004) 1.59
Responses of endothelial cell and astrocyte matrix-integrin receptors to ischemia mimic those observed in the neurovascular unit. Stroke (2007) 1.58
Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke (2009) 1.56
CT-NIHSS mismatch does not correlate with MRI diffusion-perfusion mismatch. Stroke (2007) 1.55
Acute ischemic cerebrovascular syndrome: diagnostic criteria. Stroke (2003) 1.49
Significance of early CT signs in acute stroke. A CT scan-diffusion MRI study. Cerebrovasc Dis (2002) 1.48
Acute Stroke Imaging Research Roadmap II. Stroke (2013) 1.47
Acute stroke imaging research roadmap. AJNR Am J Neuroradiol (2008) 1.41
Multivoxel MR spectroscopy in acute ischemic stroke: comparison to the stroke protocol MRI. Stroke (2012) 1.41
Acute stroke patients are being underfed: a nitrogen balance study. Neurocrit Care (2004) 1.40
Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: Insights into the pathophysiology of acute stroke in the thrombolysis era. Ann Neurol (2004) 1.40
SUMOylation participates in induction of ischemic tolerance. J Neurochem (2009) 1.38
Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis (2008) 1.37
MRI screening before standard tissue plasminogen activator therapy is feasible and safe. Stroke (2005) 1.35
The Virtual International Stroke Trials Archive. Stroke (2007) 1.34
Negative diffusion-weighted imaging after intravenous tissue-type plasminogen activator is rare and unlikely to indicate averted infarction. Stroke (2013) 1.33
Effects of intrauterine inflammation on developing rat brain. J Neurosci Res (2002) 1.31
Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab (2012) 1.30
Elevated global SUMOylation in Ubc9 transgenic mice protects their brains against focal cerebral ischemic damage. PLoS One (2011) 1.28
Trial design and reporting standards for intraarterial cerebral thrombolysis for acute ischemic stroke. J Vasc Interv Radiol (2003) 1.27
Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke (2002) 1.24
Cerebral ischemia-reperfusion injury in rats--a 3 T MRI study on biphasic blood-brain barrier opening and the dynamics of edema formation. J Cereb Blood Flow Metab (2009) 1.23
Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci U S A (2003) 1.18
Induced hypertension improves cerebral blood flow in acute ischemic stroke. Neurology (2005) 1.18
Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke (2007) 1.17
Interendothelial claudin-5 expression depends on cerebral endothelial cell-matrix adhesion by β(1)-integrins. J Cereb Blood Flow Metab (2011) 1.17
Whole-brain arterial spin labeling perfusion MRI in patients with acute stroke. Stroke (2012) 1.14
Verification of enhancement of the CSF space, not parenchyma, in acute stroke patients with early blood-brain barrier disruption. J Cereb Blood Flow Metab (2007) 1.13
TNF-alpha-induced tolerance to ischemic injury involves differential control of NF-kappaB transactivation: the role of NF-kappaB association with p300 adaptor. J Cereb Blood Flow Metab (2002) 1.12
Neuroprotection by endogenous and exogenous PACAP following stroke. Regul Pept (2006) 1.12
Accuracy and reliability assessment of CT and MR perfusion analysis software using a digital phantom. Radiology (2012) 1.11
Development and validation of a simple conversion model for comparison of intracerebral hemorrhage volumes measured on CT and gradient recalled echo MRI. Stroke (2008) 1.10
Determining the fetal inflammatory response in an experimental model of intrauterine inflammation in rats. Pediatr Res (2004) 1.10
Imaging of acute stroke. Nat Rev Neurol (2010) 1.09
Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial. Stroke (2013) 1.08
The rapid decrease in astrocyte-associated dystroglycan expression by focal cerebral ischemia is protease-dependent. J Cereb Blood Flow Metab (2007) 1.08
Regulation of Akt during torpor in the hibernating ground squirrel, Ictidomys tridecemlineatus. J Comp Physiol B (2010) 1.07
Early ischemic lesion recurrence within a week after acute ischemic stroke. Ann Neurol (2003) 1.07
Cerebral spinal fluid contamination of the measurement of the apparent diffusion coefficient of water in acute stroke. Magn Reson Med (2002) 1.04
Quantitative measurements of relative fluid-attenuated inversion recovery (FLAIR) signal intensities in acute stroke for the prediction of time from symptom onset. J Cereb Blood Flow Metab (2012) 1.03
Development, expansion, and use of a stroke clinical trials resource for novel exploratory analyses. Int J Stroke (2012) 1.02
Spectral localization by imaging using multielement receiver coils. Magn Reson Med (2011) 1.02
Stromal-derived factor-1[alpha] correlates with circulating endothelial progenitor cells and with acute lesion volume in stroke patients. Stroke (2011) 1.01
Disruption of downstream MyD88 or TRIF Toll-like receptor signaling does not protect against cerebral ischemia. Brain Res (2011) 1.01
Global protein conjugation by ubiquitin-like-modifiers during ischemic stress is regulated by microRNAs and confers robust tolerance to ischemia. PLoS One (2012) 1.00
Multiple cerebral microbleeds: MRI marker of a diffuse hemorrhage-prone state. J Neuroimaging (2004) 1.00
Involvement of Akt in preconditioning-induced tolerance to ischemia in PC12 cells. J Cereb Blood Flow Metab (2006) 0.97
Interleukin-6 174G/C polymorphism and ischemic stroke: a systematic review. Stroke (2007) 0.97
Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. Stroke (2012) 0.97
Hypertension-induced vascular remodeling contributes to reduced cerebral perfusion and the development of spontaneous stroke in aged SHRSP rats. J Cereb Blood Flow Metab (2009) 0.96
Therapeutic time window of thrombolytic therapy following stroke. Curr Atheroscler Rep (2004) 0.95
Mucosal tolerance to E-selectin promotes the survival of newly generated neuroblasts via regulatory T-cell induction after stroke in spontaneously hypertensive rats. J Cereb Blood Flow Metab (2008) 0.95
Feridex preloading permits tracking of CNS-resident macrophages after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab (2009) 0.95